Delivery Order SPE2DB22D2103-SPE2DB25FR9RD
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Tezspire 210 mg/1.91 mL pen auto-injectors. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $7,030.77 and is scheduled for completion by September 12, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a single transaction within...
- The Defense Logistics Agency awarded a $2,343.59 firm fixed price delivery order to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 mL pen auto-injectors on August 11, 2025, with completion targeted for September 2, 2025. This is a non-set-aside, competitively awarded contract under which AmerisourceBergen will deliver the specified pharmaceutical product to support federal medical supply needs. The contract represents a child delivery order under AmerisourceBergen's larger Indefinite...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $2,343.59 on August 18, 2025, for the supply of Tezspire 210 mg/1.91 ml pen injectors. This is a firm fixed price, competitively awarded delivery order with no set-aside designation and an ultimate completion date of September 9, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Tezspire 210 mg/1.91 ml pen auto-injectors. This firm fixed-price delivery order, valued at $4,687.18, carries an ultimate completion date of August 21, 2025, and represents a non-competitive award with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office...
- The Defense Logistics Agency awarded a delivery order valued at $7,030.77 to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Tezspire 210 mg/1.91 mL pen auto-injectors. The contract is non-competitive, firm fixed price delivery order with an ultimate completion date of September 8, 2025. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under a larger Indefinite Delivery Contract vehicle with the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Tezspire 210 mg/1.91 mL pen auto-injectors, valued at $2,343.59 with a firm fixed price structure. This is a non-set-aside, competitively awarded contract with an ultimate completion date of September 16, 2025. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a standard pharmaceutical...
- The Defense Logistics Agency awarded a $35,153.85 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Tezspire 210 mg/1.91 ml pen injectors. The contract, which is non-set-aside and competitively awarded, carries an ultimate completion date of September 3, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $2,343.59 to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 ml pen auto-injectors on July 31, 2025. This firm fixed-price, non-set-aside contract is scheduled for completion by August 21, 2025, with performance taking place at the vendor's corporate headquarters in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at...
- The Defense Logistics Agency awarded a delivery order valued at $2,343.59 to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Tezspire 210 mg/1.91 mL pen auto-injectors. This competitive, firm fixed-price delivery order is scheduled for completion by August 22, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Tezspire is a specialty pharmaceutical treatment used in respiratory and immunological applications, reflecting the...
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for Tezspire 210 mg/1.91 mL pen auto-injectors valued at $4,687.18, with completion scheduled for August 8, 2025. This is a firm fixed-price delivery order with no set-aside designation, meaning it was awarded through open competition. The contract is to be performed at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is a...
- SPE2DB22D2103Indefinite Delivery Contract
- SPE2DB22D2103-SPE2DB25FR9RDDelivery Order
The Defense Logistics Agency awarded a $4,687.18 delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Tezspire 210 mg/1.91 mL pen auto-injectors. This competitively awarded, firm fixed-price contract with an ultimate completion date of September 3, 2025, represents a child order under AmerisourceBergen's larger pharmaceutical supply agreement. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $1 billion global pharmaceutical support vehicle valued through December 2026. As a critical pharmaceutical distributor, AmerisourceBergen supplies the Defense Health Agency and military healthcare systems with an extensive portfolio of medications, vaccines, and medical supplies across multiple therapeutic domains. The Tezspire procurement supports military medical supply chain requirements for this specialty pharmaceutical auto-injector used in respiratory treatment protocols.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.7k | 8/12/25 |